Stockreport

SAB BIO to Participate in Upcoming Investor Conferences

SAB Biotherapeutics, Inc.  (SABS) 
PDF MIAMI, March 02, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte [Read more]